Treats Duchenne muscular dystrophy (DMD). Sold as Exondys 51. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Eteplirsen (sold as Exondys 51), first approved Sep 19, 2016, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Exondys-51 | Part D | $30.0M | +12% | 21 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical PracticeDuchenne Muscular Dystrophy · Sarepta Therapeutics, Inc. | — | Enrolling by invitation | Sep 23, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 19, 2016 | Exondys 51NDA 206488 · New molecular entity | Sarepta Theraps Inc | 8 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA